Evidence map›Paper›PMID 33253217›Full record

ArticlePloS one2020

Cardiomyocyte Oga haploinsufficiency increases O-GlcNAcylation but hastens ventricular dysfunction following myocardial infarction.

Sujith Dassanayaka, Kenneth R Brittian, Bethany W Long, Lauren A Higgins, James A Bradley, Timothy N Audam, Andrea Jurkovic, Anna M Gumpert, Linda T Harrison, István Hartyánszky and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. PERM1 regulates mitochondrial energetics through O-GlcNAcylation in the heart.Journal of molecular and cellular cardiology · 2025
    Article
  5. Matricellular protein CCN1 promotes collagen alignment and scar integrity after myocardial infarction.Matrix biology : journal of the International Society for Matrix Biology · 2024
    Article
  6. Review
  7. Review
  8. O-GlcNAcylation in ischemic diseases.Frontiers in pharmacology · 2024
    Review
  9. The O-GlcNAc dichotomy: when does adaptation become pathological?Clinical science (London, England : 1979) · 2023
    Review
  10. Review
  11. O-GlcNAcylation in Renal (Patho)Physiology.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Sujith DassanayakaDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.ORCID 0000-0002-8627-6731
Kenneth R BrittianDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
Bethany W LongDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
Lauren A HigginsDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
James A BradleyDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
Timothy N AudamDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
Andrea JurkovicDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
Anna M GumpertDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
Linda T HarrisonDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
István HartyánszkyHeart and Vascular Center, Semmelweis University, Budapest, Hungary, United states of America.
Péter PergeHeart and Vascular Center, Semmelweis University, Budapest, Hungary, United states of America.
Béla MerkelyHeart and Vascular Center, Semmelweis University, Budapest, Hungary, United states of America.
Tamás RadovitsHeart and Vascular Center, Semmelweis University, Budapest, Hungary, United states of America.
John A HanoverLaboratory of Cell and Molecular Biology, NIH-NIDDK, Bethesda, MD, United states of America.ORCID 0000-0002-3154-9878
Steven P JonesDepartment of Medicine, University of Louisville, Louisville, KY, United states of America.
University of Louisville · USSemmelweis University · HUNational Institutes of Health · US

Funding

Tumor Necrosis Factor Modulation of CPCsP01HL078825 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2005 to 2021
$37.6M
TBDP30GM127607 · NIGMS · UNIVERSITY OF LOUISVILLE · PI HILL, BRADFORD GUY · 2018 to 2022
$6.3M
Biosynthetic Pathways in Cardiac RemodelingR01HL147844 · NHLBI · UNIVERSITY OF LOUISVILLE · PI HILL, BRADFORD GUY, JONES, STEVEN P · 2019 to 2022
$3.0M
Regulation of Metabolic Genes in the HeartR01HL131647 · NHLBI · UNIVERSITY OF LOUISVILLE · PI JONES, STEVEN P · 2016 to 2019
$2.2M
NHLBI NIH HHS P01 HL078825NHLBI NIH HHS R01 HL131647NHLBI NIH HHS R01 HL147844NIGMS NIH HHS P30 GM127607
6 · The paper itself

Abstract

rationaleThe beta-O-linkage of N-acetylglucosamine (i.e., O-GlcNAc) to proteins is a pro-adaptive response to cellular insults. To this end, increased protein O-GlcNAcylation improves short-term survival of cardiomyocytes subjected to acute injury. This observation has been repeated by multiple groups and in multiple models; however, whether increased protein O-GlcNAcylation plays a beneficial role in more chronic settings remains an open question.

objectiveHere, we queried whether increasing levels of cardiac protein O-GlcNAcylation would be beneficial during infarct-induced heart failure. METHODS AND

resultsTo achieve increased protein O-GlcNAcylation, we targeted Oga, the gene responsible for removing O-GlcNAc from proteins. Here, we generated mice with cardiomyocyte-restricted, tamoxifen-inducible haploinsufficient Oga gene. In the absence of infarction, we observed a slight reduction in ejection fraction in Oga deficient mice. Overall, Oga reduction had no major impact on ventricular function. In additional cohorts, mice of both sexes and both genotypes were subjected to infarct-induced heart failure and followed for up to four weeks, during which time cardiac function was assessed via echocardiography. Contrary to our prediction, the Oga deficient mice exhibited exacerbated-not improved-cardiac function at one week following infarction. When the observation was extended to 4 wk post-MI, this acute exacerbation was lost.

conclusionsThe present findings, coupled with our previous work, suggest that altering the ability of cardiomyocytes to either add or remove O-GlcNAc modifications to proteins exacerbates early infarct-induced heart failure. We speculate that more nuanced approaches to regulating O-GlcNAcylation are needed to understand its role-and, in particular, the possibility of cycling, in the pathophysiology of the failing heart.

Indexed as

AnimalsEchocardiographyFemaleGlycosylationHaploinsufficiencyHeartHeart FailureHumansMaleMiceMice, KnockoutMiddle AgedMyocardial InfarctionMyocardiumN-AcetylglucosaminyltransferasesTamoxifenN-AcetylglucosaminyltransferasesTamoxifen

Identifiers

PMID33253217
PMCPMC7703924
OpenAlexW3109136428

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.